CNSC-45. DAILY LOCOMOTOR ACTIVITY DECLINES WITH TUMOR GROWTH AND PRECEDES CLINICAL DETECTION OF PROGRESSION IN GLIOBLASTOMA

Abstract Glioblastoma (GBM) is an aggressive brain tumor that often progresses despite resection and treatment. Early detection of GBM progression is critical to improve patient survival. Current detection approaches require costly and specialized imaging. Here, we hypothesize that monitoring daily locomotion provides a relatively inexpensive and non-invasive approach to detect GBM progression earlier. We found that wheel-running activity in GBM-bearing mice declined as tumors grew and preceded weight loss by more than a week. Temozolomide treatment in the morning, but not evening, reduced tumor size and restored daily locomotion in mice. In human GBM patients, wrist actigraphy provided a reliable longitudinal indicator of daily activity with one-minute resolution. Following tumor resection, daily activity declined before clinical detection of progression, and did not change for patients with stable disease. These results suggest that daily activity tracking may serve as a reliable indicator and potential monitoring tool for GBM progression. Supported by NIH grant R01NS134885.